Salute e Benessere
Caristo to Unveil New Clinical and Research Results at SCCT 2025
Data from the large-scale implementation of CaRi-Heart technology in five National Health Service (NHS) hospitals in the UK will reveal the technology's impact on tailoring patient management with inflammation-driven risk stratification. Latest clinical results from this real-world implementation will be presented and discussed on , featuring:
Caristo has achieved two significant U.S. regulatory milestones in 2025. In February, the Food and Drug Administration (FDA) granted clearance for Caristo's CaRi-Plaque™ technology for plaque and stenosis quantification. In March, the AMA CPT Panel approved a new Category III CPT® for Caristo's CaRi-Heart® technology for coronary inflammation detection and cardiovascular mortality risk assessment. SCCT attendees can book an exclusive demo of Caristo's CaRi-Heart and CaRi-Plaque technologies by
"We are excited to present latest clinical and research results that further validate the difference we're making in transforming health outcomes for patients," said Frank Cheng , CEO, Caristo Diagnostics.
July 17 :
July 18 :
Caristo Diagnostics is a global leader in AI-powered heart disease detection. A spinout from the University of Oxford , Caristo's award-winning technology is transforming cardiovascular care by identifying hidden heart attack risks before symptoms appear. Backed by leading hospitals and scientists, Caristo is on a mission to save lives through early detection and personalized prevention. For more information, visit caristo.com. Find Caristo online on , and .
Logo: https://mma.prnewswire.com/media/2054669/5255104/Caristo_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/caristo-to-unveil-new-clinical-and-research-results-at-scct-2025-302500066.html